#PROphetNSCLC
LightNews LightNews
newsen.bsky.social
OncoHost's PROphetNSCLC® Data Presentation at WCLC 2026 Highlights Predictive Accuracy Beyond Initial Sampling#South_Korea#Seoul#OncoHost#PROphetNSCLC#WCLC_2026
OncoHost's PROphetNSCLC® Data Presentation at WCLC 2026 Highlights Predictive Accuracy Beyond Initial Sampling
OncoHost's upcoming presentation at WCLC 2026 aims to showcase the efficacy of PROphetNSCLC® in predicting patient outcomes during treatment cycles, enhancing precision oncology.
third-news.com
September 10, 2026 at 12:16 PM
360dx.bsky.social
www.360dx.com/cancer/oncoh...
OncoHost Receives Lab Permit From New York State DOH
With the permit, the Israeli company can offer its plasma proteomics ProphetNSCLC test for guiding therapy in lung cancer patients throughout New York State.
www.360dx.com
October 22, 2025 at 2:29 PM
newsen.bsky.social
OncoHost Unveils Exciting Advances in Plasma Proteomics for NSCLC at ISLB 2025#Israel#OncoHost#NSCLC#Binyamina#PROphetNSCLC
OncoHost Unveils Exciting Advances in Plasma Proteomics for NSCLC at ISLB 2025
OncoHost showcases two innovative studies on plasma proteomics for non-small cell lung cancer monitoring and prediction at ISLB 2025, highlighting a transformative approach.
third-news.com
November 2, 2025 at 1:08 PM
newsen.bsky.social
OncoHost's PROphetNSCLC Test Now Available for Clinical Use in New York#USA#New_York#OncoHost#Precision_Oncology#PROphetNSCLC
OncoHost's PROphetNSCLC Test Now Available for Clinical Use in New York
OncoHost has secured a New York State laboratory permit, enabling the use of its innovative PROphetNSCLC test, enhancing precision oncology access.
third-news.com
October 22, 2025 at 12:54 PM
medrxivpreprint.bsky.social
Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB) https://www.medrxiv.org/content/10.1101/2024.09.09.24313374v1
Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB) https://www.medrxiv.org/content/10.1101/2024.09.09.24313374v1
Despite the approval of PD-(L)1 inhibitors for the first-line treatment of all metastatic, driver- n
www.medrxiv.org
September 11, 2024 at 4:28 PM
l2plabs.bsky.social
OncoHost Receives New York State Laboratory Permit, Expanding Availability of PROphetNSCLC® Precision Oncology Test
BINYAMINA, Israel and CARY, N.C., Oct. 22, 2025 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine through plasma proteomics and AI, today announced that it has received a laboratory permit from the New York State Department of Health Wadsworth...
dlvr.it
October 22, 2025 at 12:34 PM